Radiation-induced craniofacial bone growth inhibition: In vitro cytoprotection in the rabbit orbitozygomatic complex periosteum-derived cell culture

Plastic and Reconstructive Surgery

Volumn 121, Issue 3, 2008, Pages 763-771

  Gevorgyan, Artur M ^b   La Scala, Giorgio C ^b   Sukhu, Balram ^b   Leung, Iona T ^b   Ashrafpour, Homa ^b   Yeung, Ivan ^b   Neligan, Peter C ^b   Pang, Cho Y ^b   Forrest, Christopher R ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMIFOSTINE; COLLAGEN TYPE 1; RADIOPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE MINERALIZATION; CELL COUNT; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME SYNTHESIS; FACIAL BONE; IRRADIATION; MALE; NONHUMAN; ORBIT; OSTEOBLAST; PERIOSTEUM; PRIORITY JOURNAL; RABBIT; RADIATION DOSE; SKULL; ZYGOMA; ANIMAL; ANIMAL MODEL; BONE DEVELOPMENT; CELL CULTURE; CYTOLOGY; PATHOPHYSIOLOGY; RADIATION EXPOSURE; RADIATION INJURY;

AMIFOSTINE; ANIMALS; BONE DEVELOPMENT; CELLS, CULTURED; CYTOPROTECTION; MALE; MODELS, ANIMAL; ORBIT; OSTEOBLASTS; PERIOSTEUM; RABBITS; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; ZYGOMA;

EID: 40549088635     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000299908.66658.82     Document Type: Article

References (38)

1. Meadows, A. T., and Silber, J. Delayed consequences of therapy for childhood cancer. CA Cancer J. Clin. 35: 271, 1985.
2. Denys, D., Kaste, S. C., Kun, L. E., Chaudhary, M. A., Bowman, L. C., and Robbins, K. T. The effects of radiation on craniofacial skeletal growth: A quantitative study. Int. J. Pediatr. Otorhinolaryngol. 45: 7, 1998.
3. Larson, D. L., Kroll, S., Jaffe, N., Serure, A., and Goepfert, H. Long-term effects of radiotherapy in childhood and adolescence. Am. J. Surg. 160: 348, 1990.
4. Farkas, L. G., and Posnick, J. C. Growth and development of regional units in the head and face based on anthropometric measurements. Cleft Palate Craniofac. J. 29: 301, 1992.
5. Toljanic, J. A., Ali, M., Haraf, D. J., Vokes, E. E., Moran, W. J., and Graham, L. Osteoradionecrosis of the jaws as a risk factor in radiotherapy: A report of an eight-year retrospective review. Oncol. Rep. 5: 345, 1998.
6. Potter, B. O., and Sturgis, E. M. Sarcomas of the head and neck. Surg. Oncol. Clin. N. Am. 12: 379, 2003.
7. Zackrisson, B., Mercke, C., Strander, H., Wennerberg, J., and Cavallin-Stahl, E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 42: 443, 2003.
8. Vissink, A., Jansma, J., Spijkervet, F. K., Burlage, F. R., and Coppes, R. P. Oral sequelae of head and neck radiotherapy. Crit. Rev. Oral Biol. Med. 14: 199, 2003.
9. Paulino, A. C., Simon, J. H., Zhen, W., and Wen, B. C. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 48: 1489, 2000.
10. Dahllof, G. Craniofacial growth in children treated for malignant diseases. Acta Odontol. Scand. 56: 378, 1998.
11. Raney, R. B., Asmar, L., Vassilopoulou-Sellin, R., et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and-III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med. Pediatr. Oncol. 33: 362, 1999.
12. Guyuron, B., Dagys, A. P., Munro, I. R., and Ross, R. B. Effect of irradiation on facial growth: A 7- to 25-year follow-up. Ann. Plast. Surg. 11: 423, 1983.
13. Karsila-Tenovuo, S., Jahnukainen, K., Peltomaki, T., et al. Disturbances in craniofacial morphology in children treated for solid tumors. Oral Oncol. 37: 586, 2001.
14. Grdina, D. J., Murley, J. S., and Kataoka, Y. Radioprotectants: Current status and new directions. Oncology 63(Suppl. 2): 2, 2002.
15. Capizzi, R. L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur. J. Cancer 32A(Suppl. 4): S5, 1996.
16. Capizzi, R. L., and Oster, W. Chemoprotective and radioprotective effects of amifostine: An update of clinical trials. Int. J. Hematol. 72: 425, 2000.
17. O'Donovan, D. A., Yeung, I., Zeman, V., Neligan, P. C., Pang, C. Y., and Forrest, C. R. Radiation-induced craniofacial bone growth inhibition: Development of an animal model. J. Craniofac. Surg. 12: 533, 2001.
18. Forrest, C. R., O'Donovan, D. A., Yeung, I., et al. Efficacy of radioprotection in the prevention of radiation-induced craniofacial bone growth inhibition. Plast. Reconstr. Surg. 109: 1311, 2002.
19. La Scala, G. C., O'Donovan, D. A., Yeung, I., et al. Radiation-induced craniofacial bone growth inhibition: Efficacy of cytoprotection following a fractionated dose regimen. Plast. Reconstr. Surg. 115: 1973, 2005.
20. Bellows, C. G., Aubin, J. E., Heersche, J. N., and Antosz, M. E. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 38: 143, 1986.
21. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semi-automated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47: 936, 1987.
22. Tenenbaum, H. C., Limeback, H., McCulloch, C. A., Mamujee, H., Sukhu, B., and Torontali, M. Osteogenic phase-specific co-regulation of collagen synthesis and mineralization by beta-glycerophosphate in chick periosteal cultures. Bone 13: 129, 1992.
23. Dare, A., Hachisu, R., Yamaguchi, A., Yokose, S., Yoshiki, S., and Okano, T. Effects of ionizing radiation on proliferation and differentiation of osteoblast-like cells. J. Dent. Res. 76: 658, 1997.
24. Matsumura, S., Jikko, A., Hiranuma, H., Deguchi, A., and Fuchihata, H. Effect of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif. Tissue Int. 59: 307, 1996.
25. Dudziak, M. E., Saadeh, P. B., Mehrara, B. J., et al. The effects of ionizing radiation on osteoblast-like cells in vitro. Plast. Reconstr. Surg. 106: 1049, 2000.
26. Gal, T. J., Munoz-Antonia, T., Muro-Cacho, C. A., and Klotch, D. W. Radiation effects on osteoblasts in vitro: A potential role in osteoradionecrosis. Arch. Otolaryngol. Head Neck Surg. 126: 1124, 2000.
27. Szymczyk, K. H., Shapiro, I. M., and Adams, C. S. Ionizing radiation sensitizes bone cells to apoptosis. Bone 34: 148, 2004.
28. Orditura, M., De Vita F., Roscigno, A., et al. Amifostine: A selective cytoprotective agent of normal tissues from chemoradiotherapy induced toxicity (Review). Oncol. Rep. 6: 1357, 1999.
29. MedImmune Oncology, I. Ethyol (amifostine) for injections. 2001.
30. Brizel, D. M., Wasserman, T. H., Henke, M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18: 3339, 2000.
31. Shen, H., Chen, Z. J., Zilfou, J. T., Hopper, E., Murphy, M., and Tew, K. D. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J. Pharmacol. Exp. Ther. 297: 1067, 2001.
32. North, S., El-Ghissassi, F., Pluquet, O., Verhaegh, G., and Hainaut, P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19: 1206, 2000.
33. Pluquet, O., North, S., Richard, M. J., and Hainaut, P. Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem. Pharmacol. 65: 1129, 2003.
34. Pluquet, O., North, S., Bhoumik, A., Dimas, K., Ronai, Z., and Hainaut, P. The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J. Biol. Chem. 278: 11879, 2003.
35. Mann, K., and Hainaut, P. Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene 24: 3964, 2005.
36. Kataoka, Y., Murley, J. S., Khodarev, N. N., Weichselbaum, R. R., and Grdina, D. J. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine. Int. J. Radiat. Oncol. Biol. Phys. 53: 180, 2002.
37. Hatoum, G. F., Nevaldine, B., Bhavsar, T., Phung, Q., and Hahn, P. J. WR-1065, the active form of amifostine, protects HL-60 cells but not peripheral blood mononuclear cells from radiation and etoposide-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 59: 844, 2004.
38. Khodarev, N. N., Kataoka, Y., Murley, J. S., Weichselbaum, R. R., and Grdina, D. J. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int. J. Radiat. Oncol. Biol. Phys. 60: 553, 2004.